US FDA Sets Convalescent Plasma Access Recommendations For Coronavirus Patients

 
• By Derrick Gingery
Coronavirus
The US FDA Center for Biologics Evaluation and Research prefers that convalescent plasma treatments for coronavirus be studied in traditional clinical trials. • Source: Shutterstock

More from US FDA

More from Agency Leadership